Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo

This article was originally published in The Tan Sheet

Executive Summary

Ibuprofen Migraine Pain (Motrin Migraine Pain), cromolyn sodium nasal spray (Nasalcrom) and ibuprofen cold & sinus (Advil Cold & Sinus) are among the private-label products in the pipeline; however, the granting of pediatric exclusivity could set back their launch. Upcoming supplements from Perrigo include MSM with glucosamine, bone & joint gelatin powder (NutraJoint), calcium 600 + soy, a multivitamin with lutein, FreeFlex glucosamine (Aflexa) and two glucosamine/chondroitin products (Flexagen and Osteo-Bi-Flex) (1see related story, p. 14)

You may also be interested in...



Leiner OTC Sales Buoy Company Performance As Supplement Market Slows

Leiner Health Products is committed to reinvigorating its struggling dietary supplement business despite the sluggish market atmosphere and the recent success of the company's growing OTC portfolio.

Leiner OTC Sales Buoy Company Performance As Supplement Market Slows

Leiner Health Products is committed to reinvigorating its struggling dietary supplement business despite the sluggish market atmosphere and the recent success of the company's growing OTC portfolio.

Leiner OTC Sales Buoy Company Performance As Supplement Market Slows

Leiner Health Products is committed to reinvigorating its struggling dietary supplement business despite the sluggish market atmosphere and the recent success of the company's growing OTC portfolio.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091383

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel